Literature DB >> 18713740

Structure of protein geranylgeranyltransferase-I from the human pathogen Candida albicans complexed with a lipid substrate.

Michael A Hast1, Lorena S Beese.   

Abstract

Protein geranylgeranyltransferase-I (GGTase-I) catalyzes the transfer of a 20-carbon isoprenoid lipid to the sulfur of a cysteine residue located near the C terminus of numerous cellular proteins, including members of the Rho superfamily of small GTPases and other essential signal transduction proteins. In humans, GGTase-I and the homologous protein farnesyltransferase (FTase) are targets of anticancer therapeutics because of the role small GTPases play in oncogenesis. Protein prenyltransferases are also essential for many fungal and protozoan pathogens that infect humans, and have therefore become important targets for treating infectious diseases. Candida albicans, a causative agent of systemic fungal infections in immunocompromised individuals, is one pathogen for which protein prenylation is essential for survival. Here we present the crystal structure of GGTase-I from C. albicans (CaGGTase-I) in complex with its cognate lipid substrate, geranylgeranylpyrophosphate. This structure provides a high-resolution picture of a non-mammalian protein prenyltransferase. There are significant variations between species in critical areas of the active site, including the isoprenoid-binding pocket, as well as the putative product exit groove. These differences indicate the regions where specific protein prenyltransferase inhibitors with antifungal activity can be designed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713740      PMCID: PMC2581548          DOI: 10.1074/jbc.M805330200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Antifungal activity of a Candida albicans GGTase I inhibitor-alanine conjugate. Inhibition of Rho1p prenylation in C. albicans.

Authors:  Krishna K Murthi; Susan E Smith; Arthur F Kluge; Gustave Bergnes; Patrick Bureau; Vivian Berlin
Journal:  Bioorg Med Chem Lett       Date:  2003-06-02       Impact factor: 2.823

2.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

Authors:  T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  J Mol Biol       Date:  2004-10-15       Impact factor: 5.469

3.  Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes.

Authors:  R Kelly; D Card; E Register; P Mazur; T Kelly; K I Tanaka; J Onishi; J M Williamson; H Fan; T Satoh; M Kurtz
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

Review 4.  Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I.

Authors:  Kimberly T Lane; Lorena S Beese
Journal:  J Lipid Res       Date:  2006-02-13       Impact factor: 5.922

5.  Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution.

Authors:  H W Park; S R Boduluri; J F Moomaw; P J Casey; L S Beese
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

6.  Conversion of protein farnesyltransferase to a geranylgeranyltransferase.

Authors:  Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  Biochemistry       Date:  2006-08-15       Impact factor: 3.162

7.  Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release.

Authors:  E S Furfine; J J Leban; A Landavazo; J F Moomaw; P J Casey
Journal:  Biochemistry       Date:  1995-05-23       Impact factor: 3.162

8.  H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate.

Authors:  K E Hightower; C C Huang; P J Casey; C A Fierke
Journal:  Biochemistry       Date:  1998-11-03       Impact factor: 3.162

9.  Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.

Authors:  Heather L Hartman; Katherine E Bowers; Carol A Fierke
Journal:  J Biol Chem       Date:  2004-05-05       Impact factor: 5.157

10.  Yeast protein geranylgeranyltransferase type-I: overproduction, purification, and characterization.

Authors:  W G Stirtan; C D Poulter
Journal:  Arch Biochem Biophys       Date:  1995-08-01       Impact factor: 4.013

View more
  6 in total

Review 1.  Targeting prenylation inhibition through the mevalonate pathway.

Authors:  Pimyupa Manaswiyoungkul; Elvin D de Araujo; Patrick T Gunning
Journal:  RSC Med Chem       Date:  2019-12-23

2.  Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.

Authors:  Michael A Hast; Steven Fletcher; Christopher G Cummings; Erin E Pusateri; Michelle A Blaskovich; Kasey Rivas; Michael H Gelb; Wesley C Van Voorhis; Said M Sebti; Andrew D Hamilton; Lorena S Beese
Journal:  Chem Biol       Date:  2009-02-27

3.  Differential requirements of protein geranylgeranylation for the virulence of human pathogenic fungi.

Authors:  Ana Camila Oliveira Souza; Qusai Al Abdallah; Kaci DeJarnette; Adela Martin-Vicente; Ashley V Nywening; Christian DeJarnette; Emily A Sansevere; Wenbo Ge; Glen E Palmer; Jarrod R Fortwendel
Journal:  Virulence       Date:  2019-12       Impact factor: 5.882

Review 4.  Protein-Protein Interactions in Candida albicans.

Authors:  Floris Schoeters; Patrick Van Dijck
Journal:  Front Microbiol       Date:  2019-08-07       Impact factor: 5.640

5.  Functional and genomic analyses of alpha-solenoid proteins.

Authors:  David Fournier; Gareth A Palidwor; Sergey Shcherbinin; Angelika Szengel; Martin H Schaefer; Carol Perez-Iratxeta; Miguel A Andrade-Navarro
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

6.  In Vitro and In Silico Approaches for the Evaluation of Antimicrobial Activity, Time-Kill Kinetics, and Anti-Biofilm Potential of Thymoquinone (2-Methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione) against Selected Human Pathogens.

Authors:  Kamal A Qureshi; Mahrukh Imtiaz; Adil Parvez; Pankaj K Rai; Mariusz Jaremko; Abdul-Hamid Emwas; Avinash D Bholay; Muhammad Qaiser Fatmi
Journal:  Antibiotics (Basel)       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.